MEXICO CITY, Feb. 13 (Xinhua) – A group of Mexican scientists from the National Polytechnic Institute (IPN) are developing studies focusing on the design of neutralizing antibodies as biotherapeutic agents to fight the Chikungunya virus and improve reagents. existing diagnostics.
In an interview with journalists, Sons of Myra Peres Tapia, the executive director of the Biobrocessing Unit of the National School of Biological Sciences (ENCB), explained today that detecting antibodies and turning them into a product can have great potential for human consumption .
The study involved a multidisciplinary group of Mexican and foreign scientists.
According to Pérez Tapia, it is proposed in this first part to use an antibody detection platform, which has been built for three years with the sum of different efforts.
It is a world-class platform that has a high economic value as it is at the forefront of detecting antibodies.
"IPN has it because it has signed different agreements and unions for its construction, and it is also intended exclusively for the Mexican population," the expert explained.
Once this antibody has been detected, it says it has been shown to have some activity to neutralize or block the virus to avoid infection in in vitro systems.
"Once this is achieved, we begin to develop a product, then move to a therapeutic format where conceptual tests and preclinical tests are conducted," said the scientist.
To achieve the goals set in this study, funding has been received by the National Science and Technology Council (CONACYT), given that it is an emerging disease of international concern.
Chikungunya fever is a viral disease transmitted to humans by infected mosquitoes.
The disease is most common in Africa, Asia and the Indian subcontinent. However, since 2015, there has been a major outbreak affecting several countries in the North and South America, according to the World Health Organization (WHO).